The study compares the plasma concentrations of PF-02413873 after administration of several doses as suspension and as tablets
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
12
Single oral dose of 150 mg of PF-02413873 suspension
Single oral dose of 30 mg of PF-02413873 suspension
Single oral dose of 400 mg of PF-02413873 suspension
Pfizer Investigational Site
Singapore, Singapore
Pharmacokinetics: Cmax, AUCinf
Time frame: June - July 2009
Tmax, Tlag, AUClast, AUCt, t½, Frel.
Time frame: June-July 2009
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Single oral dose of 5 mg of PF-02413873 suspension
Single oral dose of 750 mg of PF-02413873 suspension
Single oral dose of 150 mg of PF-02413873 tablets
Single oral dose of 30 mg of PF-02413873 tablets
Single oral dose of 400 mg of PF-02413873 tablets
Single oral dose of 5 mg of PF-02413873 tablets
Single oral dose of 750 mg of PF-02413873 tablets